{"entity":{"id":"nct06911684","kind":"trial","name":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.","aka":[],"tldr":"A phase 2 trial of regorafenib in colorectal cancer, run by Sun Yat-sen University, now recruiting.","summary":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. is a phase 2, randomised interventional study registered as NCT06911684 by Sun Yat-sen University, with a registry enrolment figure of 88 participants, started 2025-04-30 and due to reach its primary completion in 2026-04-30. Interventions recorded: lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy; lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy. Conditions listed: Rectal Cancer Patients. Primary outcome: Complete response (CR). Colorectal eligibility wording from the registry: \"Pathology: Histologically confirmed rectal adenocarcinoma, with the lower tumor edge ≤12 cm from the anal verge\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06911684","url":"https://clinicaltrials.gov/study/NCT06911684"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["antiangiogenic","imrt-igrt","kinase-inhibitors"],"targets":[],"drugs":["regorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06911684","phase":"2","setting":"Short-Term Radiotherapy Combined With Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX Neoadjuvant Therapy for Locally Advanced Rectal Cancer：A Multicenter, Prospective, Randomized, Phase II Clinical Trial","sponsor":"Sun Yat-sen University","enrolled":88,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06911684/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}